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Abstract
2-Amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) is a central dietary mutagen, produced when proteinaceous food 
is heated at very high temperatures potentially causing DNA strand breaks. This study investigates the protective potential of 
a well-researched flavonoid, myricetin in its bulk and nano-forms against oxidative stress induced ex vivo/in vitro by PhIP 
in lymphocytes from pre-cancerous monoclonal gammopathy of undetermined significance (MGUS) patients and those 
from healthy individuals. The results from the Comet assay revealed that in the presence of myricetin bulk (10 µM) and 
myricetin nano (20 µM), the DNA damage caused by a high dose of PhIP (100 µM) was significantly (P < 0.001) reduced 
in both groups. However, nano has shown better protection in lymphocytes from pre-cancerous patients. Consistent results 
were obtained from the micronucleus assay where micronuclei frequency in binucleated cells significantly decreased upon 
supplementing PhIP with myricetin bulk (P < 0.01) and myricetin nano (P < 0.001), compared to the PhIP treatment alone. 
To briefly determine the cellular pathways involved in the protective role of myricetin against PhIP, we studied gene expres-
sion of P53 and ATR kinase (ATM- and Rad3-related), using the real-time PCR technique.
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Introduction
Recently, the consumption of processed and overcooked 
red meat has been associated with causing carcinogenic-
ity in humans (Bouvard et al. 2015), attributed to the pro-
duction of food-related carcinogens including heterocyclic 
amines (HCAs) (Sugimura et al. 2004). HCAs are strong 
DNA-damaging complexes which are formed when meat 
and other related products are cooked at very high tempera-
ture (Turesky and Le Marchand 2011). 2-amino-1-methyl-
6-phenylimidazo [4,5-b] pyridine (PhIP) is considered as 
the most commonly occurring HCA in our diet (Sugimura 
et al. 2004). It is metabolically activated by cytochrome 
P450 1A2 (CYP1A2) producing the toxic intermediate, 
2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-b] pyri-
dine (N–OH–PhIP) (Turesky 2007). It has been stated that 
increasing PhIP doses cause cellular death while surviving 
cells exhibit high levels of mutations, as determined in the 
hypoxanthine–guanine phosphoribosyl transferase (hprt) 
locus (Gooderham et al. 2002). Several in vivo (Cheung 
et al. 2011; Choudhary et al. 2012; Li et al. 2012) and epide-
miological studies (Cross et al. 2005; Voutsinas et al. 2013) 
reported the contribution of PhIP towards the induction of 
mammary, gastrointestinal and prostate cancers in rodents. 
C8-PhIP-dG adducts are said to interfere with the DNA rep-
lication process triggering a cellular stress response called 
replication stress mainly through DNA damage which ulti-
mately gives rise to single stranded DNA (ssDNA) (Byun 
et al. 2005). The ssDNA quickly forms an ssDNA-RPA 
complex by adjoining with the replication protein A (RPA) 
which is then detected by ATR-interacting protein (ATRIP) 
recruiting kinase ATM- and Rad3-related (ATR). Thus, 
this process triggers a DNA damage response (DDR) by 
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activating ATR (Zou and Elledges, 2003; Ball et al. 2005). 
ATR in cooperation with RPA, therefore, plays a signifi-
cant role in induction of the repair pathways and facilitates 
the restart of hindered replication forks by stabilizing them 
(Cimprich and Cortez 2008).
Myricetin, a well-studied flavonoid with diverse proper-
ties is primarily recognised due to its anti-oxidant, anti-can-
cer and anti-inflammatory activities (Ong and Khoo 1997). 
It has also been regarded as a potent chemo preventative 
agent against various tumours. Myricetin is a plant-derived 
flavonoid, mainly occurring in tea, berries, red wine, fruits 
and vegetables (Androutsopoulos et al. 2009; Kim et al. 
2014; Semwal et al. 2016). Myricetin displayed anti-geno-
toxic effects against the food mutagens, 3-amino-1-methyl-
5H-pyrido-(4,3-b) indole (Trp) and 2-amino-3-methylim-
idazo-(4,5-f) quinoline (IQ) and decreased DNA damage 
without exogenous metabolic initiation in human lympho-
cyte cells (Anderson et al. 1997).
Diet is an important contributory factor towards the devel-
opment of various cancers and knowing that lymphocytes 
express CYP1A2 and that the food mutagen, PhIP, activated 
by CYP1A2, contributes in many dietary tumours (Ander-
son et al. 1997; Cheung et al. 2011; Voutsinas et al. 2013), 
we investigated for the first time in this study the effects of 
PhIP at basal levels as well as by co-supplementation with 
either myricetin bulk (MYR B) or myricetin nano (MYR N) 
in lymphocytes from healthy individuals and pre-cancerous, 
monoclonal gammopathy of unknown significance (MGUS) 
patients.
In this study, we investigated and analysed the effects of 
PhIP treatment on the induction of DNA damage, strand 
breaks formation using the Comet plus cytogenetic damage 
in the micronucleus assays, kinase ATR regulation and p53 
levels using real-time PCR in peripheral lymphocytes from 
pre-cancerous patients and healthy individuals and also the 
modulating effects of myricetin (MYR B and MYR N) on 
PhIP-induced metabolic changes of these factors.
Methodology
Blood sample collection and Ethics
The current study which involved the use of human periph-
eral lymphocytes has been granted ethical approval by Leeds 
East Ethics Committee (Reference No. 12/YH/0464) and 
the University of Bradford’s Sub-Committee for Ethics in 
Research involving healthy Human Subjects (Reference 
No. 0405/8). The research support and governance office of 
Bradford Teaching Hospitals NHS Foundation also agreed 
the research number (REDA 1202).
The blood samples from healthy individuals and pre-
cancerous patients used in the study were collected after 
obtaining informed consent from volunteers and are listed 
in Tables 1 and 2, respectively.
Cell culture
Isolated lymphocytes from healthy individuals and pre-
cancerous patients were maintained in RPMI medium sup-
plemented with 15% foetal bovine serum (FBS) and 1% 
penicillin streptomycin (all from Invitrogen, UK) at 37 ℃ to 
be used in subsequent experiments. However, fresh blood 
samples were diluted in a 1:1 ratio with RPMI-1640 medium 
supplemented with 10% DMSO (Invitrogen, UK) and ali-
quoted volumes were immediately stored at − 80 ℃ to be 
used in the Comet assay.
Preparation and concentration of PhIP 
and myricetin
In this study two forms of myricetin (NP and bulk) and one 
form of PhIP (Toronto Research chemicals INC, Canada. 
A617000) (bulk) was used. Myricetin powder (>  96% 
purity) was purchased from Fisher Scientific, UK. Suspen-
sions of myricetin bulk, myricetin nano and PhIP were made 
in an excipient mixture (containing 7% (w/w) solid loads of 
myricetin in a medium comprising of hydroxypropyl methyl-
cellulose (HPMC) (0.5% w/w), sodium lauryl sulphate 
Table 1  Characteristics of healthy blood samples
M male, F female
No Age Ethnicity Gender Smoking 
history
Family history
1 25 Caucasian M No None
2 44 Asian M Yes None
3 28 Caucasian M No None
4 23 Caucasian F No None
5 27 Caucasian M No None
6 33 Arab M Yes None
7 47 Asian M Yes None
8 28 Caucasian M No None
9 42 Asian M No None
10 48 Asian M No None
11 60 Asian M Yes None
12 24 Asian M No None
13 34 Asian M No None
14 34 Caucasian F Yes None
15 34 Asian M No None
16 59 Caucasian F Yes None
17 28 Asian M Yes None
18 61 Caucasian F No None
19 36 Caucasian F No None
20 52 Caucasian F No None
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(SLS) (0.1% w/w), ethanol (0.8% w/w), polyvinylpyrro-
lidone (PVP) K-30 (0.5% w/w) and purified water). The 
suspensions were stored in amber glass bottles at 4 ℃ for 
the research duration. The concentrations of myricetin bulk 
(MYR B) and NP (MYR N) forms, used for this research 
study were 10 µM and 20 µM, respectively (data used from 
previous study) (Akhtar et al. 2020). The concentration of 
PhIP used throughout the study was 100 µM. These values 
were determined by concentration response curves for each 
of the chemicals. The stability of the particles for all the 
chemicals was assessed by checking their particle size and 
the difference was less than 1%. Hence, these were consid-
ered stable to be used for the study. The suspensions were 
also sonicated for 10 min before each use to avoid sedimen-
tation and control aggregation.
Cell viability
Lymphocyte viability and integrity were measured using 
trypan blue exclusion. Cells were isolated and treated with 
chemicals for 24 h supplemented with complete medium 
(RPMI media containing 1% penicillin–streptomycin and 
15% foetal bovine serum (FBS)) (all from Invitrogen, UK). 
After the incubation time was over, 10 µl of suspension was 
added to 10 µl of Trypan blue 4% (Sigma Aldrich, UK) and 
transferred to a haemocytometer for cell counting to deter-
mine viable cells.
The Comet assay
Lymphocytes were treated with MYR B and MYR N in 
combination with PhIP (100 µM) for 1 h. The cell suspen-
sion was centrifuged at 3000 rpm (1000g). The supernatant 
was removed, and the pelleted cells were used for the Comet 
assay as previously defined (Tice et al 2000; OECD 2019; 
Anderson et al. 2014; Azqueta and Dusinska 2015).
Micronucleus (MN) assay
Fresh blood samples from five healthy and five patients sup-
plemented with Phytohaemagglutinin (PHA) (Invitrogen 
ltd, UK) were added to conical flasks containing basic cul-
ture medium (RPMI 1640 with 25 mM HEPES and l-Glu-
tamine), 1% penicillin–streptomycin and 15% FBS were 
incubated for 24 h at 37 °C in the presence of 5%  CO2. The 
assay procedure was adapted as described by Fenech (OECD 
2019; Fenech 2007). To determine the frequency of MNi, 
1000 cells were scored according to criteria characterized 
by Fenech (2007).
Table 2  Characteristics of 
pre-cancerous patients’ blood 
samples
M male, F Female, MGUS monoclonal gammopathy of unknown significance, COPD chronic obstructive 
pulmonary disease
No. Age Ethnicity Gender Smoking 
history
Family history Medical condition
1 63 Caucasian M Yes None MGUS
2 75 Caucasian M No None MGUS
3 74 Caucasian F No Lung cancer MGUS
4 83 Caucasian M No None MGUS
5 60 Asian F No None MGUS
6 62 Caucasian M No None MGUS
7 51 Caucasian F No None MGUS
8 80 Caucasian M No Cancer positive MGUS
9 81 Caucasian F No Bowel and stomach MGUS
10 63 Caucasian M Yes None MGUS
11 63 Caucasian M Yes None MGUS
12 74 Caucasian M No None MGUS COPD
13 63 Caucasian F Yes Arthritis MGUS, COPD
14 66 Caucasian F No Breast cancer MGUS
15 52 Caucasian M Yes None MGUS
16 79 Caucasian M No None MGUS
17 80 Caucasian F No None MGUS
18 78 caucasian M No None MGUS
19 50 Asian F No None MGUS
20 69 Caucasian M No Stomach and lung MGUS
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Real‑time PCR analysis
Isolated lymphocytes were seeded in six-well plates and 
treated with chemicals for 24 h. Two micrograms of total 
isolated RNA was subjected to reverse transcription using 
iScript™ c DNA synthesis kit (Bio Rad, UK) according 
to the manufacturer protocol. Each real-time PCR experi-
ment was done thrice in a total of 10 µl reaction mixtures. 
Data were analysed using the 2-DDCt method (Livak and 
Schmittgen 2001) and normalised against the internal 
home gene GAPDH in each sample.
Statistical analysis
All the experiments were conducted at least three times. 
Graph Pad prism 7 was used to perform statistical analy-
sis. The results were analysed using one-way analysis of 
variance (ANOVA) and two-way ANOVA to test differ-
ences between each treatment and the control. A P value 
of < 0.05 was considered statistically significant.
Results
Concentration response curve for PhIP
The optimal dose of PhIP inducing maximum DNA dam-
age was determined using the Comet assay in lympho-
cytes from healthy vs patient group. PhIP concentrations 
(50–200 µM) were considered for the test by comparing 
against the untreated group. 50 µM hydrogen peroxide 
 (H2O2) was used as a standard positive control. Results 
demonstrate that all doses of PhIP have induced significant 
(P < 0.001) DNA damage in healthy lymphocytes (Fig. 1). 
Although there was little difference between the three con-
centrations (50, 100 and 200 µM), 100 µM was used as a 
standard which caused maximum DNA damage in both 
groups. Hence, it was used throughout the study.
Viability of lymphocytes
There was no significant effect observed on viability of 
lymphocytes from healthy individuals and those from pre-
cancerous patients after 24 h treatment with various treat-
ment groups used in this study except for PhIP + MYR 
N. However, viability for this group was also assessed at 
more than 86% in both healthy and patient lymphocytes 
(Fig. 2). This confirms that the concentration of chemicals 
used throughout the study were non-toxic for the lympho-
cyte cells.
Modulating effects of MYR B and MYR N 
on PhIP‑induced DNA damage in lymphocytes using 
the Comet assay
To determine the in vitro effects of different particle sizes 
of myricetin on PhIP-induced DNA damage, lymphocytes 
from healthy volunteers and pre-cancerous patients were 
treated with either MYR B (10 µM) or MYR N (20 µM) 
simultaneously co-supplemented with PhIP (100 µM). 
Results demonstrated a reduction in DNA damage over-
all, when compared against the PC (PhIP 100 µM). The 
damage was significantly decreased by both forms of myri-
cetin in healthy lymphocytes as well as in those from pre-
cancerous patients assessed using the two parameters of 
the Comet assay, Olive tail moment (OTM) and % Tail 
Fig. 1  Concentration dependent responses of PhIP in lymphocytes 
from healthy individuals and pre-cancerous patient lymphocyte show-
ing mean %Tail DNA. All PhIP doses induced genotoxic damage to 
the cells whereas 100 µM seemed to produce maximum DNA dam-
age in both groups. All data have been expressed as mean ± standard 
errors (SE). *** P < 0.001, ** P < P < 0.01, ns not significant
Fig. 2  % viability per 100 cells counted/treatment after 24 h. Treat-
ment groups used were untreated (NC), excipient mixture (Em), 
positive control (PC) PhIP 100  µM, PhIP supplemented with MYR 
B (10  µM) and MYR N (20  µM). Viability was calculated as more 
than 80% for all the treatment groups. (ns not significant, *P < 0.02, 
** P < P < 0.004)
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DNA. However, only OTM (Figs. 3, 4) data have been 
showed because of similar results. The levels were almost 
returning to those similar to the negative control. This 
indicates that MYR B and MYR N exhibit similar protec-
tive and anti-genotoxic effects and can potentially protect 
the lymphocytes of healthy individuals and pre-cancerous 
patients against the DNA damage and genotoxicity caused 
by PhIP.
Determination of micronuclei (MNi)
MNi frequency in binucleated cells (BiNC)
The effect of PhIP alone and combination of PhIP with MYR 
B or MYR N on micronuclei formation was assessed using 
the micronucleus assay. Our results show that the number 
of MNi in BiNC cells from pre-cancerous patients was 
higher than those from healthy individuals in their respec-
tive untreated groups. There were few MNi observed in the 
healthy NC group per 1000 cells counted, and this needs to 
be taken into consideration when evaluating these results. 
This frequency was further enhanced by exposing the cells 
to PhIP (100 µM) (P < 0.001). However, simultaneous addi-
tion of MYR B or MYR N has significantly reduced MNi 
formation induced by PhIP in BiNC cells from healthy indi-
viduals and pre-cancerous patients (Table 3).
Other elements of MN
Table 3 shows that there is no significant difference between 
the NDI and % of BiNC for all treatment groups when com-
pared to the respective untreated group for healthy individu-
als and pre-cancerous patients. PhIP significantly induced 
MNi formation in both groups. Untreated cultures of patient 
groups have shown higher numbers of MNi both in MoNC 
and BiNC as compared to the groups treated with MYR B 
and MYR N. MYR B (10 µM) or MYR N (20 µM) addi-
tion with PhIP has significantly reduced the MNi induction 
regardless of group difference and cell type (Table 3).
Activation of the P53 and ATR signalling 
pathways by myricetin bulk and nanoparticles 
following PhIP‑induced oxidative stress
Built on earlier results, we found that MYR B and MYR N 
have shown protective effects against PhIP-induced DNA 
damage in lymphocytes from healthy individuals and pre-
cancerous patients. To identify the molecular mechanism 
involved in this effect, we studied the influences of PhIP 
and then myricetin co-supplementation with PhIP on the 
gene expression levels of P53, a tumour-suppressor multi-
functional gene and ATR kinase mRNA in lymphocytes. 
The results (Fig. 5) have shown that in healthy lympho-
cytes, PhIP treatment significantly decreased the P53 gene 
expression to 0.5-fold, however, this was significantly up-
regulated upon supplementation with MYR B to 1.4-fold 
and with MYR N to a 1.75-fold increase. In lymphocytes 
from the patient group the P53 was slightly down-regulated 
Fig. 3  Modulating effect of MYR B & N on PhIP-induced DNA 
damage in healthy lymphocytes using Olive Tail Moment. The above 
figure shows five treatment groups including an untreated group, the 
positive control (PhIP 100 µM), MYR B (10 µM) with PhIP, MYR N 
(20 µM) supplemented with PhIP and excipient mixture (EM) (0.1%). 
The PC and EM were compared against the NC while MYR B and 
MYR N against the PC. The mean NC and PC values for healthy 
groups were 1 and 6 respectively. ***Represents P < 0.001, ns not 
significant. The horizontal lines on top of the graph show the signifi-
cant difference between the treatment groups
Fig. 4  Modulating effect of MYR B and N on PhIP-induced DNA 
damage in pre-cancerous patient lymphocytes using Olive Tail 
Moment. The above figure shows five treatment groups including an 
untreated group, the positive control (PhIP 100 µM), MYR B (10 µM) 
with PhIP, MYR N (20 µM) supplemented with PhIP and excipient 
mixture (EM) (0.1%). The PC and EM were compared against the NC 
while MYR B and MYR N against the PC. The mean NC and PC 
values for healthy groups were 3 and 7, respectively. *** P < 0.001, 
ns = not significant. The horizontal lines on top of the graph show the 
significant difference between the treatment groups
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with PhIP treatment, whereas significantly up-regulated by 
MYR N co-supplementation (P < 0.01). PhIP has shown dif-
ferent effects on gene expression levels of ATR in lympho-
cytes from healthy individuals to those from pre-cancerous 
patients. The ATR gene was significantly (P < 0.001) up-
regulated by PhIP in healthy lymphocytes and it was further 
enhanced by myricetin supplementation where MYR N has 
shown P < 0.001 significance. However, PhIP has demon-
strated reverse effects on ATR expression in lymphocytes 
from the patient group. It significantly down-regulated the 
ATR gene levels (P < 0.01) which were significantly up-
regulated by myricetin addition. These results indicate that 
protective effects caused by myricetin on PhIP-induced dam-
age might be dependent on the tumour-suppression activity 
of the P53 gene. The mechanisms involved in diverse ATR 
regulation by PhIP in lymphocytes from healthy individuals 
compared to those from pre-cancerous patients are not fully 
understood.
Discussion
This study focused on the effects of the food mutagen, PhIP 
in lymphocytes from pre-cancerous patients compared to 
those from healthy individuals and the modulating effects 
of myricetin against PhIP-induced damage. PhIP has previ-
ously been shown to be genotoxic producing DNA adducts 
(Brown et al. 2001) and contributing towards the forma-
tion of dietary cancers (Cheung et al. 2011; Voutsinas et al. 
2013). First, we demonstrated that PhIP induces significant 
levels of DNA damage and strand breaks in lymphocytes 
from healthy and patient groups, determined by the Comet 
Table 3  The average of 
various markers/parameters of 
chromosomal damage in the 
cytokinesis-block micronucleus 
assay
Showing NDI per treatments on healthy and patient cells (all values compared against respective untreated 
group), mean % of BiNC (all values compared against respective untreated group), mean number of MNI 
in BiNC and MNi frequency in MoNC (For these two columns, the PC is compared against the respective 
NC (untreated lymphocytes). However, co-supplemented groups (MYR B + PhIP, MYR N + PhIP) were 
compared against their respective PC)
Subject Treatment Group NDI % BiNC MNi in MoNC MNi in BiNC
Healthy individuals NC 1.85 62 0 0
PhIP (PC) 1.63 (ns) 62 (ns) 7 (P < 0.001) 15 (P < 0.001)
MYR B + PhIP 1.83 (ns) 61 (ns) 4 (P < 0.01) 10 (P < 0.01)
MYR N + PhIP 1.63 (ns) 61 (ns) 3 (P < 0.01) 8 (P < 0.001)
Pre-cancerous patients NC 1.81 61 6 6
PhIP (PC) 1.78 (ns) 61 (ns) 12 (P < 0.001) 13 (P < 0.001)
MYR B + PhIP 1.73 (ns) 60 (ns) 8 (P < 0.01) 9 (P < 0.01)
MYR N + PhIP 1.80 (ns) 60 (ns) 7 (P < 0.01) 6 (P < 0.001)
Fig. 5  The expression of ATR and P53 mRNA in lymphocyte from 
healthy individuals (a) and pre-cancerous patients (b) after treat-
ing with PhIP (100  µM), MYR B (10  µM) with PhIP and MYR N 
(20  µM) supplemented with PhIP. GAPDH was used as an internal 
control gene. Gene expression analysis was performed on lympho-
cytes after 24-h treatment. Values are the means of three independent 
experiments, and the error bars represent SDs. (*P < 0.01, **P < 0.01, 
***P < 0.001, ns not significant). Horizontal lines on the graph repre-
sent the difference between the groups. Data were compared against 
the control (c). All data were normalised against GAPDH reference 
gene
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and the micronucleus assays (P < 0.001), supporting previ-
ous studies (Mimmler et al. 2016; Buonarati et al. 1990; 
Boobis et al. 1994). Results from the micronucleus assay 
have shown a significant induction of MNi formation in 
BiNC after treatment with PhIP alone (P < 0.001). A MN 
formed in BiNC only depicts the damage caused after the 
treatment, hence reducing the probability of scoring the pre-
existing damage (Magdelenova et al. 2012). In micronucleus 
assay, we had to rely on results deducted from 1000 cells 
scored per treatment group due to manual scoring. However, 
in future, automated micronucleus scoring techniques could 
be applied to score a much greater number of cells making 
the effect more apparent.
Our results confirm that PhIP being a genotoxic agent 
in the absence of toxicity causes significant DNA damage 
in lymphocytes from healthy individuals and those from 
pre-cancerous patients. However, upon treatment with 
myricetin (MYR B 10 µM and MYR N 20 µM), PhIP-
induced damage was reduced to a substantial level 
presented by both the Comet and cytokinesis-block 
micronucleus assays (Figs. 3, 4 and Table 3). Both the 
control lymphocytes and patient lymphocytes showed 
high sensitivity to PhIP in the Comet assay. Lymphocytes 
from the pre-cancerous patients had an increased level of 
basal damage due to the disease condition. Confounding 
factors (age, ethnicity, gender etc.) of both investigative 
groups were best possibly matched and their effects on 
DNA damage were determined. There was no relationship 
established between any of the confounders and the DNA 
damage in healthy and patient groups (Table 4).
It is believed that food mutagens damage the DNA by 
producing ROS and flavonoids act in an anti-oxidant man-
ner to reduce this damage (Kurzawa et al. 2012). Therefore, 
DNA damage caused by PhIP in lymphocytes from both 
investigative groups could possibly be because of dual mech-
anisms: CYP1A2-induced or ROS-induced genotoxicity.
Previous studies have shown that the apical DDR kinases 
such as ATR and ATM can be directly activated by DNA 
adducts apart from the replication-dependent stimulation 
(Choi et al. 2007, 2009; Kemp et al. 2011). Based on our 
results from the Comet assay, we established that PhIP 
induces strand breaks and that myricetin protects against 
their induction. Hence, to understand the DDR elicited by 
PhIP and myricetin, we investigated the gene expression 
levels of ATR kinase and the tumour-suppressor gene P53 
in lymphocytes from healthy individuals and pre-cancerous 
patients. Similar patterns of results were obtained for the 
P53 gene in lymphocytes from both groups. P53 was down-
regulated upon PhIP treatment, whereas MYR B and MYR 
N supplementation had shown significant attenuation of 
PhIP-triggered effects and increased the expression of P53 
to substantial levels.
However, PhIP has shown diverse effects on the ATR 
kinase activity in both investigative groups. It has signifi-
cantly increased the ATR gene regulation in healthy lym-
phocytes which was further enhanced by myricetin supple-
mentation (P < 0.001). This was in agreement with previous 
studies that upon provoking replication stress, PhIP acti-
vates ATR–CHK1 pathway in V79 CS cells (Mimmler et al. 
2016). These results propose that myricetin may protect 
against the mutagenicity caused by PhIP in healthy lympho-
cytes by triggering the activation of ATR in P53-mediated 
DDR pathway. Hence, contribute towards the survival path 
by initiating repair mechanism.
On the other hand, PhIP significantly (P < 0.01) down-
regulated the ATR kinase activity, in lymphocytes from the 
patient group. However, myricetin effectively weakened the 
effects of PhIP and significantly increased ATR regulation. 
Table 4  The effect of confounding factors
Confounding factors such as age, ethnicity, gender and smoking were analysed using the Comet assay and results demonstrated that various 
chemicals used in this study had no significantly different effects on either of the comparison group. Comparison was made between the varia-
tions within the confounding factor
ns not significant
Subject Treatment Group Smoker Non-smoker Asian Caucasian Male Female Young Old
OTM OTM OTM OTM OTM OTM OTM OTM
Healthy individuals NC 1.1 0.7 ns 0.7 0.7 ns 1.2 0.8 ns 2.7 4.1 ns
PC (PhIP 50 µM) 9.1 10.7 ns 10.4 9.2 ns 8.3 12.0 ns 9.7 10.0 ns
MYR B (10 µM) 2.0 1.5 ns 1.1 2.0 ns 1.5 1.3 ns 3.1 6.0 ns
MYR N (20 µM) 1.5 0.8 ns 1.4 0.9 ns 2.0 1.2 ns 1.6 3.1 ns
Pre-cancerous patients NC 3.6 2.8 ns 4.0 2.5 ns 2.2 2.6 ns 3.5 3.2 ns
PC (PhIP 50 µM) 9.0 10.2 ns 15.8 13.2 ns 6.2 5.6 ns 9.6 11.0 ns
MYR B
(10 µM)
2.5 3.4 ns 6.9 3.8 ns 2.6 3.3 ns 3.9 4.5 ns
MYR N (20 µM) 2.3 1.7 ns 4.0 2.9 ns 1.0 1.8 ns 2.1 3.1 ns
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Since the ATR inhibition and increased sensitivity caused 
by PhIP in patient lymphocytes and the protection shown 
by myricetin were both dependent on the P53 pathway. This 
suggests that myricetin could potentially induce apoptosis in 
PhIP-treated lymphocytes from pre-cancerous patients. Also, 
the protection depicted by myricetin against PhIP-induced 
damage may be attributed to its anti-tumour activity by 
stimulating the levels of the P53-tumour-suppressor gene.
The overall findings from the current study confirm that 
myricetin is effectively able to prevent the DNA of lympho-
cytes from healthy and pre-cancerous MGUS patients from 
PhIP-induced DNA damage. This could possibly be made 
clinically applicable by maintaining the plasma concentra-
tions of myricetin through regular intake.
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